gabapentin has been researched along with Benign Neoplasms, Brain in 10 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Excerpt | Relevance | Reference |
---|---|---|
"Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs." | 5.29 | Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996) |
"Patients undergoing craniotomy received either placebo (group D) or gabapentin (600 mg) (group GD) premedication orally, 2 hours before induction of anesthesia." | 5.17 | The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors. ( Misra, S; Parthasarathi, G; Vilanilam, GC, 2013) |
"Therefore, the optimal seizure management by antiepileptic drugs (AEDs) in this patient category is essentially unsure." | 2.43 | Optimal seizure management in brain tumor patients. ( van Breemen, MS; Vecht, CJ, 2005) |
"Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs." | 1.29 | Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 3 (30.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Krishna, S | 1 |
Choudhury, A | 1 |
Keough, MB | 1 |
Seo, K | 1 |
Ni, L | 1 |
Kakaizada, S | 1 |
Lee, A | 1 |
Aabedi, A | 1 |
Popova, G | 1 |
Lipkin, B | 1 |
Cao, C | 1 |
Nava Gonzales, C | 1 |
Sudharshan, R | 1 |
Egladyous, A | 1 |
Almeida, N | 1 |
Zhang, Y | 1 |
Molinaro, AM | 1 |
Venkatesh, HS | 1 |
Daniel, AGS | 1 |
Shamardani, K | 1 |
Hyer, J | 1 |
Chang, EF | 1 |
Findlay, A | 1 |
Phillips, JJ | 1 |
Nagarajan, S | 1 |
Raleigh, DR | 1 |
Brang, D | 1 |
Monje, M | 1 |
Hervey-Jumper, SL | 1 |
Corona-Ramos, JN | 1 |
Déciga-Campos, M | 1 |
Romero-Piña, M | 1 |
Medina, LA | 1 |
Martínez-Racine, I | 1 |
Jaramillo-Morales, OA | 1 |
García-López, P | 1 |
López-Muñoz, FJ | 1 |
Laghari, AA | 1 |
Ahmed, SI | 1 |
Qadeer, N | 1 |
Shamim, MS | 1 |
Mari, Z | 1 |
Rosenthal, LS | 1 |
Darwin, KC | 1 |
Hallett, M | 1 |
Jinnah, HA | 1 |
Misra, S | 2 |
Parthasarathi, G | 1 |
Vilanilam, GC | 1 |
Crespo Pérez, L | 1 |
Moreira Vicente, V | 1 |
Cano Ruiz, A | 1 |
Gobernado Serrano, JM | 1 |
Cobo Ibañez, N | 1 |
Milicua Salamero, JM | 1 |
Koshy, T | 1 |
Unnikrishnan, KP | 1 |
Suneel, PR | 1 |
Chatterjee, N | 1 |
Porzio, G | 1 |
Aielli, F | 1 |
Narducci, F | 1 |
Varrassi, G | 1 |
Ricevuto, E | 1 |
Ficorella, C | 1 |
Marchetti, P | 1 |
van Breemen, MS | 1 |
Vecht, CJ | 1 |
Perry, JR | 1 |
Sawka, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
Intervention | score on 10-point scale (Mean) |
---|---|
Standard of Care | 2.26 |
Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
Intervention | score on a 10-point scale (Mean) |
---|---|
Standard of Care | 3.84 |
Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
Intervention | score on a 10-point scale (Mean) |
---|---|
Standard of Care | 5.73 |
Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
Intervention | score on a 10-point scale (Mean) |
---|---|
Standard of Care | 0.36 |
Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
Intervention | score on a 10-point scale (Mean) |
---|---|
Standard of Care | 7.83 |
Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
Intervention | days (Mean) |
---|---|
Standard of Care | 14.8 |
Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
Intervention | morphine equivalents (Mean) |
---|---|
Standard of Care | 287.0 |
Postoperative Gabapentin Regimen | 281.1 |
4 reviews available for gabapentin and Benign Neoplasms, Brain
Article | Year |
---|---|
Choice of therapeutic anti-seizure medication in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L | 2019 |
Clinical Reasoning: a 57-year-old man with jaw spasms.
Topics: Adrenergic Uptake Inhibitors; Amines; Anticonvulsants; Brain Neoplasms; Cyclohexanecarboxylic Acids; | 2013 |
[Anticonvulsant hypersensitivity syndrome: an entity to be remembered].
Topics: Adolescent; Amines; Anemia, Hemolytic; Anticonvulsants; Astrocytoma; Brain Neoplasms; Carbamazepine; | 2009 |
Optimal seizure management in brain tumor patients.
Topics: Amines; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cyclohexanecarboxylic Acids; Drug I | 2005 |
2 trials available for gabapentin and Benign Neoplasms, Brain
Article | Year |
---|---|
The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors.
Topics: Adult; Amines; Anesthesia; Anti-Inflammatory Agents; Brain Neoplasms; Craniotomy; Cyclohexanecarboxy | 2013 |
Gabapentin premedication decreases the hemodynamic response to skull pin insertion in patients undergoing craniotomy.
Topics: Adolescent; Adult; Amines; Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Local; Blood P | 2011 |
4 other studies available for gabapentin and Benign Neoplasms, Brain
Article | Year |
---|---|
Glioblastoma remodelling of human neural circuits decreases survival.
Topics: Biopsy; Brain; Brain Neoplasms; Cell Proliferation; Cognition; Disease Progression; Gabapentin; Glio | 2023 |
The Effect of Gabapentin and Tramadol in Cancer Pain Induced by Glioma Cell in Rat Femur.
Topics: Amines; Analgesics; Animals; Bone Neoplasms; Brain Neoplasms; Cancer Pain; Cell Line, Tumor; Cell Su | 2017 |
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases.
Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Neoplasms; Carcinoma, Small Cell; Colonic Neoplasms; | 2003 |
Add-on gabapentin for refractory seizures in patients with brain tumours.
Topics: Acetates; Amines; Anticonvulsants; Brain Neoplasms; Cyclohexanecarboxylic Acids; Follow-Up Studies; | 1996 |